Virpax Pharmaceuticals, Inc. (VRPX) Bundle
A Brief History of Virpax Pharmaceuticals, Inc. (VRPX)
Founding and Early Years
Virpax Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Radnor, Pennsylvania. The company focuses on developing innovative therapeutics and drug delivery systems primarily for pain management and central nervous system (CNS) disorders.
Initial Public Offering
On August 2021, Virpax Pharmaceuticals went public on the NASDAQ under the ticker symbol VRPX. The IPO raised approximately $20 million to support its product development initiatives.
Key Products in Development
Virpax has several product candidates in various stages of development:
- Probudur: An intranasal formulation for post-operative pain management.
- EN379: A novel solution for the treatment of ocular pain, currently in late-stage development.
- VRP324: A formulation targeting the management of chronic pain associated with Osteoarthritis.
Strategic Partnerships
In 2022, Virpax entered into a partnership with Thermo Fisher Scientific for the production and manufacturing of its drug candidates. This partnership was estimated to enhance production capabilities and streamline the supply chain.
Financial Performance
As of the end of 2022, Virpax reported total assets of approximately $15 million and a net loss of around $9 million. The company’s current cash position was noted to be approximately $4 million, which is allocated towards ongoing clinical trials and operational expenses.
| Year | Total Assets | Net Loss | Cash Position |
|---|---|---|---|
| 2021 | $10 million | $5 million | $3 million |
| 2022 | $15 million | $9 million | $4 million |
Regulatory Milestones
Virpax received FDA Fast Track designation for Probudur in 2021, which facilitated more frequent interactions with the FDA during the development process.
Recent Developments
In March 2023, Virpax announced promising results from a Phase 2 clinical trial for Probudur, showing statistically significant pain relief compared to placebo.
Market Position and Future Outlook
As of 2023, Virpax Pharmaceuticals is positioning itself to be a leader in the pain management market with a pipeline of innovative products that leverage advanced drug delivery technologies.
A Who Owns Virpax Pharmaceuticals, Inc. (VRPX)
Ownership Structure
As of the latest filings, the ownership structure of Virpax Pharmaceuticals, Inc. (VRPX) is delineated based on institutional and insider holdings. Here is a detailed breakdown:
| Owner Type | Owner Name | Percentage Owned | Shares Held |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 4.5% | 500,000 |
| Institutional Investor | Renaissance Technologies LLC | 3.2% | 350,000 |
| Insider | Dr. Charles M. Rowland | 10.0% | 1,100,000 |
| Insider | James A. Nascimento | 6.0% | 660,000 |
| Institutional Investor | Vanguard Group, Inc. | 2.8% | 310,000 |
Recent Developments
The most recent developments affecting ownership include stock performance and new institutional investments. As of October 2023, the stock price of VRPX was approximately $5.50 per share. The market capitalization for Virpax Pharmaceuticals, Inc. stood around $100 million.
Shareholder Composition
The following table depicts a more detailed composition of the shareholder base:
| Holder Type | Number of Shareholders | Total Shares Held | Average Shares per Holder |
|---|---|---|---|
| Insider Holders | 5 | 3,500,000 | 700,000 |
| Institutional Holders | 10 | 2,150,000 | 215,000 |
| Retail Investors | 2,000 | 1,000,000 | 500 |
Recent Financial Performance
Virpax Pharmaceuticals reported its financial results for Q3 2023, highlighting the following key figures:
| Financial Metric | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|
| Revenue | $0.5 million | $0.3 million | $0.2 million |
| Net Income | -$2.0 million | -$1.8 million | -$1.5 million |
| Cash and Cash Equivalents | $7.5 million | $8.0 million | $9.0 million |
Stock Performance and Market Sentiment
Current stock performance reflects investor sentiment and market conditions:
| Metric | Value |
|---|---|
| Current Stock Price | $5.50 |
| 52-Week High | $10.00 |
| 52-Week Low | $4.00 |
| Volume (30-Day Avg) | 150,000 shares |
Future Outlook
Analysts project modest growth for Virpax Pharmaceuticals with anticipated developments in product pipeline and partnerships affecting future ownership stakes.
Virpax Pharmaceuticals, Inc. (VRPX) Mission Statement
Corporate Vision
Corporate Vision
Virpax Pharmaceuticals aims to be a leader in the development and commercialization of innovative pharmaceutical products that improve patient outcomes. The company is focused on addressing unmet medical needs through the advancement of its proprietary technology platforms.
Core Values
- Integrity: Commitment to ethical practices in all operations.
- Innovation: Continuous improvement and adaptation of cutting-edge technologies.
- Collaboration: Fostering partnerships with healthcare professionals and organizations.
- Patient-Centricity: Prioritizing the health and well-being of patients in all endeavors.
Strategic Objectives
The mission statement reflects Virpax's dedication to several strategic objectives:
- Develop novel therapeutic products with significant market potential.
- Advance pipeline projects: EP-101, and other product candidates.
- Expand partnerships with industry leaders to enhance research capabilities.
Financial Performance
As of September 30, 2023, Virpax Pharmaceuticals has reported the following financial figures:
| Financial Metric | Amount (in USD) |
|---|---|
| Market Capitalization | $44.76 million |
| Total Assets | $18.09 million |
| Total Liabilities | $3.36 million |
| Revenue (Last Fiscal Year) | $0.00 (no revenue reported) |
| Net Income (Last Fiscal Year) | -$7.58 million |
| Cash and Cash Equivalents | $11.68 million |
Research and Development Focus
Virpax Pharmaceuticals is dedicated to scientific research aimed at developing innovative drug delivery systems. This includes:
- Utilizing polymer-based technologies to enhance bioavailability.
- Targeting pain management through non-opioid solutions.
- Exploring applications of nasal and oral drug delivery methods.
Regulatory Compliance
Virpax adheres to strict regulatory standards set forth by the FDA and other governing bodies to ensure that all products meet the necessary safety and efficacy benchmarks before commercialization.
Community Impact
The mission extends beyond business interests into making a significant impact in the community through:
- Engaging in partnerships with patient advocacy groups.
- Supporting education and awareness initiatives related to chronic pain management.
Looking Ahead
Virpax Pharmaceuticals is poised to make significant strides in the pharmaceutical landscape, with future plans focusing on:
- Expanding its research initiatives.
- Launching products that align with its mission of improving patient outcomes.
Investment Opportunities
Current and potential investors are presented with opportunities to engage with a biotech company on the cusp of innovative therapeutic development:
- Share price as of last trading: $1.33
- 52-week price range: $0.70 - $3.30
How Virpax Pharmaceuticals, Inc. (VRPX) Works
Company Overview
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) focuses on developing and commercializing innovative pharmaceutical products. The company's primary aim is to address unmet medical needs through a range of therapeutic areas, including pain management and other neurological conditions.
Business Model
Virpax operates on a biopharmaceutical business model that involves:
- Research and Development (R&D)
- Partnerships and Collaborations
- Regulatory Approval Processes
- Commercialization of Products
Current Projects and Pipeline
The pipeline of Virpax includes several candidates that have reached various stages of development:
| Product Name | Indication | Development Stage | Expected Milestones |
|---|---|---|---|
| VIR-210 | Postoperative Pain | Phase 2 | 2023 |
| VIR-222 | Anxiety/Stress | Preclinical | 2024 |
| VIR-225 | Neurodegenerative Disorders | Phase 1 | 2023 |
Financial Overview
As of the latest quarterly report, Virpax has reported the following financial figures:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue | $0 |
| Net Loss | $(6.2) million |
| Cash and Cash Equivalents | $10.5 million |
| Total Assets | $15.8 million |
| Total Liabilities | $5.3 million |
Market Position and Competitors
Virpax competes with other biopharmaceutical companies in the pain management sector, including:
- Amgen Inc. (AMGN)
- Pfizer Inc. (PFE)
- Johnson & Johnson (JNJ)
Regulatory Pathway
The company engages in rigorous regulatory pathways to ensure compliance, primarily through the U.S. Food and Drug Administration (FDA). The company focuses on:
- Investigational New Drug (IND) applications
- New Drug Applications (NDA)
- Clinical Trial Oversight
Funding and Investment
Virpax Pharmaceuticals has secured funding through various means, including:
- Public offerings
- Private placements
- Grants for research initiatives
| Funding Source | Amount (USD) |
|---|---|
| Public Offering (2022) | $10 million |
| Private Placement (2023) | $5 million |
| Research Grants | $2 million |
Collaborative Efforts
Virpax engages in collaborations with academic institutions and pharmaceutical entities to enhance R&D capabilities. Notable collaborations include:
- Collaboration with the University of Pennsylvania
- Partnership with various contract research organizations (CROs)
How Virpax Pharmaceuticals, Inc. (VRPX) Makes Money
Product Development and Revenue Streams
Product Development and Revenue Streams
Virpax Pharmaceuticals focuses on developing innovative drug delivery systems for pain management and central nervous system (CNS) disorders. Their primary revenue streams include:
- Licensing agreements
- Partnerships with pharmaceutical companies
- Grant funding for research and development
- Future product sales upon market approval
Current Product Pipeline
As of October 2023, Virpax has several programs in their product pipeline. The most notable is:
| Drug Candidate | Indication | Stage of Development | Projected Market Size |
|---|---|---|---|
| Envelta | Chronic Pain | Phase 2 | $10 billion (2025 estimated) |
| VPX-864 | Neuropathic Pain | Preclinical | $5 billion (2025 estimated) |
| VPX-ATU | Acute Pain | Phase 1 | $3 billion (2025 estimated) |
Financial Performance
As of the latest filings, Virpax Pharmaceuticals reported the following financial data:
| Fiscal Year | Revenue ($ million) | Net Loss ($ million) | Cash and Cash Equivalents ($ million) |
|---|---|---|---|
| 2022 | 0.5 | (5.3) | 15.0 |
| 2023 (Projected) | 1.2 | (6.5) | 12.8 |
Collaborations and Partnerships
Virpax has formed strategic collaborations as part of its business model:
- Partnered with Kaneka Corporation for the development of drug delivery systems.
- Collaboration with universities for research on novel drug formulations.
Investment and Funding
The company has raised capital through various financing rounds:
| Financing Round | Date | Amount Raised ($ million) | Type |
|---|---|---|---|
| Series A | February 2021 | 5.0 | Equity |
| IPO | December 2021 | 15.0 | Public Offering |
| Private Placement | March 2022 | 12.0 | Debt |
Market Challenges and Outlook
Virpax faces several market challenges:
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Dependence on successful clinical trials
Future Projections
The company anticipates potential milestones in the coming years:
- Market approval for Envelta by 2025
- Expansion of pipeline candidates into advanced trials by 2024
Virpax Pharmaceuticals, Inc. (VRPX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support